The Frequency ofBRAFMutation in Very Small Papillary Thyroid Carcinomas
暂无分享,去创建一个
Yoon-La Choi | S. Kang | J. Kwon | Y. Oh | Taeeun Kim | Jiwon Roh | H. Park
[1] D. Heo,et al. Differential effects between cyclooxygenase‐2 inhibitors and siRNA on vascular endothelial growth factor production in head and neck squamous cell carcinoma cell lines , 2010, Head & neck.
[2] Y. Youn,et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAFV600E mutation, clinicopathological features, and immunohistochemical findings , 2009, Head & neck.
[3] Eun-Kyung Kim,et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. , 2009, Radiology.
[4] Ji Soo Kim,et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. , 2009, Thyroid : official journal of the American Thyroid Association.
[5] H. Min,et al. Immunohistochemical and Molecular Characteristics of Follicular Patterned Thyroid Nodules with Incomplete Nuclear Features of Papillary Thyroid Carcinoma , 2009 .
[6] M. Gao,et al. Analysis of Differential BRAFV600E Mutational Status in High Aggressive Papillary Thyroid Microcarcinoma , 2009, Annals of Surgical Oncology.
[7] M. Hočevar,et al. Papillary thyroid microcarcinoma: Prognostic factors and treatment , 2008, Journal of surgical oncology.
[8] M. Santoro,et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. , 2007, Thyroid : official journal of the American Thyroid Association.
[9] N. O. Küçük,et al. Treatment for Microcarcinoma of the Thyroid—Clinical Experience , 2007, Clinical nuclear medicine.
[10] O. Sheils,et al. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model , 2007, Molecular cancer.
[11] U. Löhrs,et al. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. , 2006, Gynecologic oncology.
[12] S. Y. Park,et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. , 2006, Cancer.
[13] Tae Yong Kim,et al. The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.
[14] T. Giordano,et al. Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas , 2006, The American journal of surgical pathology.
[15] E. Pearce,et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. , 2006, The Journal of clinical endocrinology and metabolism.
[16] Tae Yong Kim,et al. The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma , 2005 .
[17] G. Sakorafas,et al. Papillary thyroid microcarcinoma: a surgical perspective. , 2005, Cancer treatment reviews.
[18] Kyung-Hee Kim,et al. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis , 2005, Pathology international.
[19] Young Kun Kim,et al. The Relationship between the BRAF Mutations in Thyroid Papillary Carcinomas and the Prognostic Factors , 2005 .
[20] M. Xing,et al. BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.
[21] P. Argani,et al. The V599E BRAF mutation is uncommon in biliary tract cancers , 2004, Modern Pathology.
[22] Kyung-Hee Kim,et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. , 2004, Yonsei medical journal.
[23] A. Pinchera,et al. BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas , 2004 .
[24] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.
[25] H. Namba,et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.
[26] V. Trovisco,et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC , 2003, Oncogene.
[27] A. Miyauchi,et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. , 2003, Thyroid : official journal of the American Thyroid Association.
[28] Yuri E Nikiforov,et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.
[29] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[30] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[31] D. Wynford‐Thomas,et al. Sporadic ret‐rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? , 1998, The Journal of pathology.
[32] L. Mariani,et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] B. J. Harrison,et al. Papillary microcarcinoma of the thyroid gland , 1996, The British journal of surgery.